WO2022240240A1 - Nk 세포의 동결보존용 조성물 및 이를 포함하는 동결보존 제형 - Google Patents
Nk 세포의 동결보존용 조성물 및 이를 포함하는 동결보존 제형 Download PDFInfo
- Publication number
- WO2022240240A1 WO2022240240A1 PCT/KR2022/006901 KR2022006901W WO2022240240A1 WO 2022240240 A1 WO2022240240 A1 WO 2022240240A1 KR 2022006901 W KR2022006901 W KR 2022006901W WO 2022240240 A1 WO2022240240 A1 WO 2022240240A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cryopreservation
- composition
- cell
- present
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 191
- 239000000203 mixture Substances 0.000 title claims abstract description 176
- 238000005138 cryopreservation Methods 0.000 title claims abstract description 145
- 238000009472 formulation Methods 0.000 title claims abstract description 79
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 77
- 239000002577 cryoprotective agent Substances 0.000 claims abstract description 47
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229940089468 hydroxyethylpiperazine ethane sulfonic acid Drugs 0.000 claims abstract description 27
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims abstract description 26
- 229940050526 hydroxyethylstarch Drugs 0.000 claims abstract description 26
- DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 claims abstract description 22
- 210000002865 immune cell Anatomy 0.000 claims description 48
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 229920001223 polyethylene glycol Polymers 0.000 claims description 44
- 201000011510 cancer Diseases 0.000 claims description 43
- 238000002659 cell therapy Methods 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 32
- 239000002202 Polyethylene glycol Substances 0.000 claims description 29
- 238000007710 freezing Methods 0.000 claims description 27
- 230000008014 freezing Effects 0.000 claims description 27
- 208000015181 infectious disease Diseases 0.000 claims description 23
- 208000035473 Communicable disease Diseases 0.000 claims description 22
- 208000026278 immune system disease Diseases 0.000 claims description 21
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 18
- 239000008103 glucose Substances 0.000 claims description 17
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 15
- 102000007562 Serum Albumin Human genes 0.000 claims description 9
- 108010071390 Serum Albumin Proteins 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 8
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 8
- 229940050410 gluconate Drugs 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 239000011591 potassium Substances 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 3
- 125000000647 trehalose group Chemical group 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 abstract description 150
- 239000000243 solution Substances 0.000 abstract description 64
- 230000000694 effects Effects 0.000 abstract description 33
- 238000010257 thawing Methods 0.000 abstract description 31
- 239000003814 drug Substances 0.000 abstract description 22
- 238000011282 treatment Methods 0.000 abstract description 17
- 230000005880 cancer cell killing Effects 0.000 abstract description 11
- 239000012595 freezing medium Substances 0.000 abstract description 11
- 230000001988 toxicity Effects 0.000 abstract description 8
- 231100000419 toxicity Toxicity 0.000 abstract description 8
- 230000007774 longterm Effects 0.000 abstract description 4
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000002458 cell surface marker Substances 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 239000000872 buffer Substances 0.000 description 50
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 30
- 239000006228 supernatant Substances 0.000 description 27
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 21
- 239000002609 medium Substances 0.000 description 20
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 18
- 210000002381 plasma Anatomy 0.000 description 16
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 15
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 239000012980 RPMI-1640 medium Substances 0.000 description 13
- 231100000331 toxic Toxicity 0.000 description 12
- 230000002588 toxic effect Effects 0.000 description 12
- 239000004698 Polyethylene Substances 0.000 description 11
- 239000008188 pellet Substances 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 230000002265 prevention Effects 0.000 description 10
- 230000035899 viability Effects 0.000 description 10
- 239000011534 wash buffer Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 102000009027 Albumins Human genes 0.000 description 8
- 108010088751 Albumins Proteins 0.000 description 8
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 8
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 8
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 8
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 238000004017 vitrification Methods 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 6
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 6
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 5
- 102000004503 Perforin Human genes 0.000 description 5
- 108010056995 Perforin Proteins 0.000 description 5
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229930192851 perforin Natural products 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 4
- 239000012099 Alexa Fluor family Substances 0.000 description 4
- 102100038077 CD226 antigen Human genes 0.000 description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 description 4
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 4
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 238000002617 apheresis Methods 0.000 description 4
- 239000005441 aurora Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 229940054269 sodium pyruvate Drugs 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000001398 Granzyme Human genes 0.000 description 3
- 108060005986 Granzyme Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 206010052015 cytokine release syndrome Diseases 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940081860 plasma-lyte 148 Drugs 0.000 description 3
- 229940095642 plasma-lyte 56 Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 2
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 101001009604 Mus musculus Granzyme B(G,H) Proteins 0.000 description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000959 cryoprotective effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- -1 hydroxylethyl Chemical group 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- LPZOCVVDSHQFST-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CC LPZOCVVDSHQFST-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010024291 Leukaemias acute myeloid Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108050003738 Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 1
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- BMXYSAJAHZRXDU-DRSQBWEGSA-H calcium magnesium potassium disodium ethanone (2S)-2-hydroxybutanedioic acid hexachloride undecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Mg++].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca++].C[C-]=O.O[C@@H](CC(O)=O)C(O)=O BMXYSAJAHZRXDU-DRSQBWEGSA-H 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940045426 kymriah Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940081858 plasmalyte a Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940034080 provenge Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 108010078373 tisagenlecleucel Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229940045208 yescarta Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
Definitions
- a low-speed freezing method such as a slow programmable freezing (SPF) method developed in the 1970s is used worldwide (Fertility and Sterility. 93 (6): 1921-8).
- SPF slow programmable freezing
- cells are coated with cryoprotectants such as dimethyl sulfoxide (DMSO), glycerol, and hydroxylethyl starch (HES) to prevent formation of ice crystals inside/outside cells. method is used.
- DMSO dimethyl sulfoxide
- HES hydroxylethyl starch
- cryoprotectants exhibits inherent toxicity, and since they are concentrated in cells during the freezing process, they are fatal to immune cell therapy or may be toxic when administered to patients later ( Peer J. 3: e1039).
- cryoprotectants such as dimethyl sulfoxide (DMSO) and hydroxyethyl starch (HES) are reported to exhibit high toxicity to human cells (Transfusion and Apheresis Science 46 (2012) 137-147).
- DMSO dimethyl sulfoxide
- HES hydroxyethyl starch
- cryopreservation formulations containing cryoprotectants add additional processing and associated costs to cell production and preservation processes.
- cryoprotectants alone are accompanied by the problem of loss of cell activity and viability. Therefore, there is a need to develop a cryopreservation method and formulation capable of maintaining the activity of immune cell therapeutics during subsequent reconstitution while minimizing the concentration of toxic additives in the composition of a solution for cryopreservation of immune cell therapeutics.
- the present invention also provides a pharmaceutical composition for preventing or treating cancer, immune disease or infectious disease comprising NK cells and the composition for cryopreservation.
- cryoprotectant selected from the group consisting of glucose, polyethylene glycol and trehalose.
- the base solution may be characterized in that it includes any one or more of sodium, chloride, potassium, magnesium, acetate and gluconate, preferably sodium, chloride, potassium, magnesium, acetate and gluconate It may be characterized by including.
- the osmolality of the base solution is about 200 mOsm/L to about 400 mOsm/L, preferably about 250 mOsm/L to about 350 mOsm/L, more preferably about 280 mOsm /L to about 310 mOsm/L, most preferably about 300 mOsm/L or about 294 mOsm/L.
- the base solution may be characterized in that it occupies the remaining composition fraction except for the preferred composition ratio of other components to be described below.
- the albumin may be characterized as plasma albumin, preferably human plasma albumin.
- DMSO Dimethylsulfoxide
- DMSO Dimethylsulfoxide
- DMSO Dimethylsulfoxide
- DMSO is reported to cause various cell damages due to non-specific cytotoxicity (Transfusion and Apheresis Science 46 (2012) 137-147; and Bone Marrow Transplant 2003;31(11):1043-51 etc). It has been reported that the cell damage mechanism of DMSO is due to rapid increase in intracellular osmotic pressure and mitochondrial damage.
- composition for cryopreservation of the present invention may be characterized in that it contains a low concentration of DMSO.
- the DMSO is about 0.001% (v / v) or more and less than about 10% (v / v), preferably about 0.005% (v / v) to about 8% (v / v), more preferably It may be characterized in that it is included in a final concentration of about 0.1% (v / v) to about 6% (v / v), most preferably about 5% (v / v).
- the present invention is characterized by including at least one cryoprotectant selected from the group consisting of glucose, polyethylene glycol and trehalose.
- the polyethylene glycol has an average molecular weight of about 400 g / mol, from about 0.01% (w / v) to about 10% (w / v), preferably from about 0.02% (w / v) About 6% (w/v), more preferably from about 0.045% (w/v) to about 2.5% (w/v), most preferably from about 0.625% (w/v) to about 2.5% (w/v) It may be characterized in that it is included in the final concentration of v).
- the polyethylene glycol has an average molecular weight of about 4000 g / mol, about 0.01% (w / v) to about 10% (w / v), preferably about 0.02% (w / v) to About 6% (w/v), more preferably from about 0.045% (w/v) to about 2.5% (w/v), most preferably from about 0.225% (w/v) to about 2.25% (w/v) It may be characterized in that it is included in the final concentration of v).
- NK cells preferably, it may be characterized in that it is a composition for cryopreservation of NK cells consisting of:
- cryoprotectant selected from the group consisting of glucose, polyethylene glycol and trehalose.
- the pH of the base solution may be about 4.0 to about 8.0, preferably about 6.0 to about 8.0, more preferably about 7.0 to about 8.0, and most preferably about 7.4.
- the polyethylene glycol has an average molecular weight of about 400 g / mol, from about 0.01% (w / v) to about 10% (w / v), preferably from about 0.02% (w / v) About 6% (w/v), more preferably from about 0.045% (w/v) to about 2.5% (w/v), most preferably from about 0.625% (w/v) to about 2.5% (w/v) It may be characterized in that it is included in the final concentration of v).
- cryoprotectant when the cryoprotectant is trehalose, about 0.5% (w / v) to about 10% (w / v), preferably about 1% (w / v) to about 9% (w / v) ), more preferably at a final concentration of about 1.7% (w/v) to 8.5% (w/v).
- the human plasma albumin is at a final concentration of about 1% (w/v) to about 10% (w/v), preferably about 2% (w/v) to about 8% (w/v). ), more preferably, about 3% (w / v) to about 5% (w / v), most preferably about 4% (w / v).
- the present invention relates to a cryopreservation formulation of NK cells comprising NK cells and the composition for cryopreservation of the present invention.
- a cryopreservation formulation is prepared by suspending cells in the cryopreservation composition of the present invention, a vial containing the cryopreservation formulation is placed in a container box for freezing containing isopropyl alcohol, and placed in an ultra-low temperature freezer for several hours to several tens of hours. It may be performed by freezing the cells by dropping the temperature constantly for a period of time, but is not limited thereto.
- the immune cell therapy may be characterized in that it is used after thawing the cryopreserved NK cryopreservation formulation of the present invention.
- the immune cell therapy may be characterized in that it is ready to use after thawing.
- Ready to use means that after thawing, it can be used/administered immediately at a pharmaceutically effective concentration without a separate dilution/concentration, reconstitution or rehydration process.
- the immune cell therapy of the present invention is in a ready-to-use form, user convenience is improved, and errors that may occur during dilution/concentration, reconstitution, or rehydration are minimized. It has the advantage of being able to prevent activity deviation and contamination due to
- 'infectious disease' is a disease caused by infection with a virus or pathogen, and is a concept that includes all diseases that can be transmitted and infected through respiratory, blood, and skin contact.
- infectious diseases include hepatitis B and C, human papilloma virus (HPV) infection, cytomegalovirus infection, viral respiratory disease, influenza, etc., but are not limited thereto. not.
- prevention refers to any action that suppresses or delays the progression of cancer, immune disease or infectious disease by administration of the pharmaceutical composition for prevention or treatment of the present invention
- treatment refers to cancer, immune disease or suppression of the development of an infectious disease, alleviation or elimination of symptoms.
- the pharmaceutical composition for prevention or treatment of the present invention may include at least one known active ingredient having a therapeutic effect on cancer, immune disease or infectious disease together with the NK cells and the composition for cryopreservation of the present invention.
- the pharmaceutical composition for prevention or treatment of the present invention can be administered through various routes including oral, transdermal, subcutaneous, intravenous or intramuscular, and the dosage of the active ingredient depends on the route of administration, the age, sex, weight and severity of the patient.
- the pharmaceutical composition for prevention or treatment according to the present invention may be appropriately selected according to various factors such as, etc., and the pharmaceutical composition for prevention or treatment according to the present invention can be administered in combination with a known compound having an effect of preventing, improving or treating symptoms of cancer, immune disease or infectious disease. can
- NK activation beads in the NK Cell Activation/Expansion Kit (Cat#: 130-112-968) (Miltenyi Biotec, Bergisch Gladbach, Germany)
- 500 ⁇ L Anti-Biotin MACSiBead Particles were added, mixed, 300 ⁇ L MACS buffer was added, and mixed for 2 hours at 2-8°C using a microtube rotator.
- NK activation beads per 1x10 6 cells to a new tube
- 1 mL NK MACS medium Cat#: 130-094-483 (Miltenyi Biotec, Bergisch Gladbach, Germany) and centrifuged at 300 ⁇ g for 5 minutes.
- NK MACs medium (Miltenyi Biotec, Bergisch Gladbach, Germany, Cat#: 130-094-483) based on 5 ⁇ L per 10 6 NK cells to release NK activation beads.
- the NK cells prepared in Example 1 were suspended in the composition for cryopreservation of NK cells at 1x10 6 cells/mL to prepare a frozen formulation of NK cells, dispensed into vials by 1ml, and stored in a cryogenic freezer for one day. , transferred to LN2 and cryopreserved.
- Example 1 As a result of confirming the viable cell number and viability of NK cells frozen for 4 weeks according to Example 1, as shown in FIG. 1, based on the NK cells stored frozen in the frozen formulation using the control group (CS10), it was confirmed that the frozen formulations using the candidate groups in Table 1 showed substantially equivalent levels of cell yield and viability. Among them, the yields of candidate groups 1-2 to 1-3, candidate groups 2-1 to 2-2, and candidate group 3-2 were added tended to be high, and candidate group 2-1 containing PEG as a stabilizer showed the highest yield. Yield is shown.
- Fc blocking solution prepared by 200X Fc block (Biolegend, San Diego, CA, USA) solution at 1X concentration in FACS buffer was added to each well was added and left on ice for 10 minutes.
- FITC-labeled anti-human CD3 antibody FITC anti-human CD3 Antibody (Clone UCHT1)
- PE-Cy7-labeled anti-human CD56 antibody PE/Cyanine7 anti-human CD56 (NCAM) Antibody (Clone 5.1H11)
- BV421-labeled anti-human CD14 antibody Brilliant Violet 421TM anti-human CD14 Antibody (Clone 63D3)
- BV480-labeled anti-human CD19 antibody BV480 Mouse Anti-Human CD19 (Clone SJ25C1)
- PE -labeled anti-human CD16 antibody PE anti-human CD16 Antibody (Clone 3G8)
- BV711-labeled anti-human NKp46 antibody Brilliant Violet 711 TM anti-human CD335 (NKp46) Antibody (Clone 9E2)
- BD HorizonTM BV650 Mouse Anti-Human CD3 antibody BD HorizonTM BV650 Mouse Anti-Human CD
- Example 5 Identification of cytotoxic markers of cryopreserved NK cells
- Fc blocking solution prepared by 200X Fc block (Biolegend, San Diego, CA, USA) at 1X concentration in FACS buffer was added to each well and iced. was left on for 10 minutes.
- PerCP-labeled anti-human CD3 Antibody (Clone HIT3a), APC-Cy7-labeled anti-human CD56 antibody (APC/Cyanine7 anti-human CD56 (NCAM) Antibody (Clone 5.1H11) ), BV421-labeled anti-human Tim-3 antibody (Brilliant Violet 421TM anti-human CD366 (Tim-3) Antibody (Clone F38-2E2)), BV785-labeled anti-human CD16 antibody (Brilliant Violet 785TM Anti-human CD16 Antibody (Clone 3G8)) and PE-labeled anti-human PD-1 antibody (PE anti-human CD279 (PD-1) Antibody (Clone A17188B)) were added to each well with 50 ⁇ L FACS buffer. After reacting at 4° C. temperature for 20 minutes, 100 ⁇ L FACS buffer was added and centrifuged at 1,300 rpm for 5 minutes.
- BD Perm/WashTM buffer was diluted to 1X concentration in DW and reacted for 30 minutes. Then, 100 ⁇ L of the prepared wash buffer was added to each well and centrifuged at 1,300 rpm for 5 minutes. Remove the supernatant, add 200 ⁇ L wash buffer, and centrifuge at 1,300 rpm for 5 minutes.
- Example 6-1 100uL each of the stained target cells of Example 6-1 was dispensed into the 96-well-plate prepared in 6-2, and the cells were co-cultured at 37° C. and 5% CO2 for 4 hours by blocking light. After co-culture, after centrifugation at 2000 rpm for 3 minutes, 100 uL of the supernatant was obtained and dispensed into a new flat bottom 96-well-plate, and fluorescence was measured at wavelengths of 485 nm and 535 nm (FIGS. 4 to 6).
- the viable cell number and viability of frozen NK cells for 2 weeks were measured using an ADAM cell counter Accustain kit (DigitalBio) according to the manufacturer's manual.
- the chip was inserted into an ADAM counter and the number of viable cells was measured, and the results are shown in FIG. 7 . According to the results of FIG. 7 , it was confirmed that the yield and viability of Candidate Groups 2-3 to 2-7 after thawing and Comparative Example 2 were at the same level.
- PerCP anti-human CD3 Antibody (Clone HIT3a), PE-Cy7 Mouse Anti-Human CD56 (NCAM-1) Clone B159)), Alexa Fluor® 700 labeled anti-human CD14 antibody (Alexa Fluor® 700 Mouse Anti-Human CD14 (Clone M5E2)), BV786 labeled anti-human CD19 antibody (BV786 Mouse Anti-Human CD19 ( Clone SJ25C1)), APC-H7 labeled anti-human CD16 antibody (APC-H7 Mouse Anti-Human CD16 (Clone 3G8)), BV711 labeled anti-human NKp46 antibody (Brilliant Violet 711TM anti-human CD335 ( NKp46) Antibody (Clone 9E2)), PE-CF594-labeled anti-human NKG2D antibody (PE-CF594 Mouse Anti-Human CD314 (NKG2D) (Clone 1D11)), BV421-labeled anti-human NKG2C
- Example 10 Identification of NK cell cytotoxicity markers of compositions for cryopreservation by PEG molecular weight
- NK MACS medium 10 mL of NK MACS medium (NK MACS medium, Miltenyi), and centrifuged at 1,300 rpm for 5 minutes. The supernatant was removed and 10 mL of NK MACS medium was added to dissolve the pellet.
- PerCP-labeled anti-human CD3 Antibody (Clone HIT3a), APC-Cy7-labeled anti-human CD56 antibody (APC/Cyanine7 anti-human CD56 (NCAM) Antibody (Clone 5.1H11) ), BV421-labeled anti-human Tim-3 antibody (Brilliant Violet 421TM anti-human CD366 (Tim-3) Antibody (Clone F38-2E2)), BV785-labeled anti-human CD16 antibody (Brilliant Violet 785TM Anti-human CD16 Antibody (Clone 3G8)) and PE-labeled anti-human PD-1 antibody (PE anti-human CD279 (PD-1) Antibody (Clone A17188B)) were added to each well with 50 ⁇ L FACS buffer. After reacting at 4° C. temperature for 20 minutes, 100 ⁇ L FACS buffer was added and centrifuged at 1,300 rpm for 5 minutes.
- BD Perm/WashTM buffer was diluted to 1X concentration in DW and reacted for 30 minutes. Then, 100 ⁇ L of the prepared wash buffer was added to each well and centrifuged at 1,300 rpm for 5 minutes. Remove the supernatant, add 200 ⁇ L wash buffer, and centrifuge at 1,300 rpm for 5 minutes.
- Example 11 Confirmation of cancer cell killing ability of NK cells of composition for cryopreservation by PEG molecular weight
- NK cells frozen for 4 weeks with each cryopreservation formulation were obtained, centrifuged at 1,300 rpm for 10 minutes, and then suspended in RPMI 1640 medium (Welgene, LM011-01) at a concentration of 1x10 6 cells/mL.
- the ratio shown in Table 15 was dispensed into a 96-well-plate according to the E:T ratio (10:1, 3:1, 1:1, 0.3:1).
- 200uL of RPMI 1640 medium was added and set as “MM”.
- cryoprotectants that exhibit various side effects due to non-specific toxicity are not included or included in low concentrations and replaced with non-toxic biocompatible cryoprotectants, the patient immediately thaws without additional culture or replacement of the solution with an injection solution. It has the advantage that it can be administered to the body and can be used as a pharmaceutical formulation. Therefore, it is very useful for long-term storage and clinical use of NK cell-based immunotherapeutic agents used for the treatment of very limited indications.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (17)
- 다음을 포함하는 NK 세포의 동결보존용 조성물:(i) 베이스 용액(base solution);(ii) 혈장 알부민(serum albumin);(iii) DMSO; 및(iv) 글루코스, 폴리에틸렌글리콜 및 트레할로스(Trehalose)로 구성된 군에서 선택되는 어느 하나 이상의 동결보호제.
- 제1항에 있어서, 상기 베이스 용액은 나트륨, 클로라이드, 칼륨, 마그네슘, 아세테이트 및 글루코네이트 중 어느 하나 이상을 포함하는 것을 특징으로 하는 NK 세포의 동결보존용 조성물.
- 제1항에 있어서, 상기 베이스 용액의 pH는 4.0 내지 8.0 인 것을 특징으로 하는 NK 세포의 동결보존용 조성물.
- 제1항에 있어서, 상기 베이스 용액의 삼투몰농도는 200 mOsm/L 내지 400 mOsm/L 인 것을 특징으로 하는 NK 세포의 동결보존용 조성물.
- 제1항에 있어서, 상기 DMSO는 0.001%(v/v) 내지 10%(v/v)의 최종농도로 포함되는 것을 특징으로 하는 NK 세포의 동결보존용 조성물.
- 제1항에 있어서, HEPES(Hydroxyethyl piperazine Ethane Sulfonicacid) 또는 HES(Hydroxy Ethyl Starch)를 포함하지 않는 것을 특징으로 하는 NK 세포의 동결보존용 조성물.
- 제1항에 있어서, 상기 혈장 알부민은 1%(w/v) 내지 10%(w/v)의 최종 농도로 포함되는 것을 특징으로 하는 NK 세포의 동결보존용 조성물.
- 제1항에 있어서, 상기 동결보호제는 글루코스, 폴리에틸렌글리콜 및 트레할로스(Trehalose)로 구성된 군에서 선택되는 어느 하나인 것을 특징으로 하는 NK 세포의 동결보존용 조성물.
- 제8항에 있어서, 상기 동결보호제는 글루코스이고, 상기 글루코스는 0.5%(w/v) 내지 5%(w/v) 의 최종농도로 포함되는 것을 특징으로 하는 NK 세포의 동결보존용 조성물.
- 제8항에 있어서, 상기 동결보호제는 폴리에틸렌글리콜이고, 상기 폴리에틸렌글리콜은 400g/mol 내지 20000g/mol의 평균 분자량을 갖는 것을 특징으로하는 NK 세포의 동결보존용 조성물.
- 제8항에 있어서, 상기 동결보호제는 폴리에틸렌글리콜이고, 상기 폴리에틸렌글리콜은 0.045%(w/v) 내지 2.5%(w/v)의 최종농도로 포함되는것을 특징으로 하는 NK 세포의 동결보존용 조성물.
- 제8항에 있어서, 상기 동결보호제는 트레할로스이고, 상기 트레할로스는 5%(w/v) 내지 10%(w/v)의 최종농도로 포함되는(include)것을 특징으로 하는 NK 세포의 동결보존용 조성물.
- NK 세포; 및 제1항 내지 제12항 중 어느 한 항의 동결보존용 조성물을 포함하는 NK 세포의 동결보존 제형.
- NK 세포를 상기 제1항 내지 제12항 중 어느 한 항의 동결보존용 조성물에 현탁하여 NK 세포 동결보존 제형을 제조하는 단계; 및상기 NK 세포 동결보존 제형을 동결시키는 단계를 포함하는 NK세포의 동결보존 방법.
- NK 세포; 및 제1항 내지 제12항 중 어느 한 항의 동결보존용 조성물을 포함하는 면역세포 치료제.
- NK 세포; 및 제1항 내지 제12항 중 어느 한 항의 동결 보존용 조성물을 포함하는 암, 면역 질환 또는 감염성 질환의 예방 또는 치료용 약학 조성물.
- 제13항의 NK 세포의 동결보존 제형을 이용한 암, 면역 질환 또는 감염성 질환의 예방 또는 치료방법.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL308334A IL308334A (en) | 2021-05-14 | 2022-05-13 | A compound for cryopreservation of NK cells and a formulation for cryopreservation consisting of the same |
BR112023023457A BR112023023457A2 (pt) | 2021-05-14 | 2022-05-13 | Composição para criopreservação de células nk e formulação de criopreservação compreendendo a mesma |
EP22807887.9A EP4338591A1 (en) | 2021-05-14 | 2022-05-13 | Composition for nk cell cryopreservation, and cryopreservation formulation comprising same |
JP2023570249A JP2024519222A (ja) | 2021-05-14 | 2022-05-13 | NK細胞の凍結保存用組成物及びこれを含む凍結保存剤形{NK cell cryopreservation composition and cryopreservation formulation comprising the same} |
CN202280034209.2A CN117715518A (zh) | 2021-05-14 | 2022-05-13 | 用于自然杀伤细胞冷冻保存的组合物以及包含其的冷冻保存制剂 |
CA3217757A CA3217757A1 (en) | 2021-05-14 | 2022-05-13 | Composition for nk cell cryopreservation, and cryopreservation formulation comprising same |
AU2022274645A AU2022274645A1 (en) | 2021-05-14 | 2022-05-13 | Composition for nk cell cryopreservation, and cryopreservation formulation comprising same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210062683 | 2021-05-14 | ||
KR10-2021-0062683 | 2021-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022240240A1 true WO2022240240A1 (ko) | 2022-11-17 |
Family
ID=84028706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/006901 WO2022240240A1 (ko) | 2021-05-14 | 2022-05-13 | Nk 세포의 동결보존용 조성물 및 이를 포함하는 동결보존 제형 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4338591A1 (ko) |
JP (1) | JP2024519222A (ko) |
CN (1) | CN117715518A (ko) |
AU (1) | AU2022274645A1 (ko) |
BR (1) | BR112023023457A2 (ko) |
CA (1) | CA3217757A1 (ko) |
IL (1) | IL308334A (ko) |
TW (1) | TW202302122A (ko) |
WO (1) | WO2022240240A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100158873A1 (en) * | 2006-09-15 | 2010-06-24 | Christian Pinset | Method for extracting and selecting cells |
CN108064840A (zh) * | 2017-12-28 | 2018-05-25 | 重庆斯德姆生物技术有限公司 | 一种nkt细胞冻存液及其制备方法 |
US20190000070A1 (en) * | 2015-06-30 | 2019-01-03 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for the cryopreservation of cells for therapeutic purposes |
CN110250162A (zh) * | 2019-07-05 | 2019-09-20 | 北京太东生物科技有限公司 | 生物样品冷冻保护剂及其应用 |
WO2021041399A1 (en) * | 2019-08-29 | 2021-03-04 | Board Of Regents, The University Of Texas System | Cell cryopreservation medium |
-
2022
- 2022-05-13 EP EP22807887.9A patent/EP4338591A1/en not_active Withdrawn
- 2022-05-13 BR BR112023023457A patent/BR112023023457A2/pt unknown
- 2022-05-13 IL IL308334A patent/IL308334A/en unknown
- 2022-05-13 AU AU2022274645A patent/AU2022274645A1/en active Pending
- 2022-05-13 WO PCT/KR2022/006901 patent/WO2022240240A1/ko active Application Filing
- 2022-05-13 JP JP2023570249A patent/JP2024519222A/ja active Pending
- 2022-05-13 CN CN202280034209.2A patent/CN117715518A/zh active Pending
- 2022-05-13 CA CA3217757A patent/CA3217757A1/en active Pending
- 2022-05-13 TW TW111118132A patent/TW202302122A/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100158873A1 (en) * | 2006-09-15 | 2010-06-24 | Christian Pinset | Method for extracting and selecting cells |
US20190000070A1 (en) * | 2015-06-30 | 2019-01-03 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for the cryopreservation of cells for therapeutic purposes |
CN108064840A (zh) * | 2017-12-28 | 2018-05-25 | 重庆斯德姆生物技术有限公司 | 一种nkt细胞冻存液及其制备方法 |
CN110250162A (zh) * | 2019-07-05 | 2019-09-20 | 北京太东生物科技有限公司 | 生物样品冷冻保护剂及其应用 |
WO2021041399A1 (en) * | 2019-08-29 | 2021-03-04 | Board Of Regents, The University Of Texas System | Cell cryopreservation medium |
Non-Patent Citations (17)
Title |
---|
"Adoptive Cell Therapy TIL", 9 July 2020, CANCER RESEARCH INSTITUTE |
A. STOLZING ET AL., TRANSFUSION AND APHERESIS SCIENCE, vol. 46, 2012, pages 137 - 147 |
ANTICANCER RES, vol. 18, no. 6B, 1998, pages 4705 - 8 |
BONE MARROW TRANSPLANT, vol. 25, no. 2, 2000, pages 173 - 7 |
CANCER LETTERS, vol. 472, 2020, pages 175 - 180 |
CRYO LETTERS, vol. 25, no. 4, pages 241 - 54 |
CYTOTHERAPY, vol. 1, no. 6, 1999, pages 439 - 46 |
EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 1, no. 4, pages 641 - 53 |
FERTILITY AND STERILITY, vol. 93, no. 6, pages 1921 - 8 |
FRONTIERS IN IMMUNOLOGY, vol. 10, 2019, pages 2683 |
FRONTIERS IN IMMUNOLOGY, vol. 10, no. 2019, pages 2683 |
G. ALLAHBADIA ET AL.: "Vitrification in Assisted Reproduction", 2015, SPRINGER INDIA |
NATURE, vol. 313, no. 6003, pages 573 - 5 |
NEUROLOGY, vol. 68, no. 11, 2007, pages 859 - 61 |
PEER J, vol. 3, pages e1039 |
ROWLEY S.D., BONE MARROW TRANSPLANT, vol. 31, no. 11, 2003, pages 1043 - 51 |
TRANSFUSION, vol. 31, no. 2, 1991, pages 138 - 41 |
Also Published As
Publication number | Publication date |
---|---|
EP4338591A1 (en) | 2024-03-20 |
AU2022274645A1 (en) | 2024-01-04 |
BR112023023457A2 (pt) | 2024-01-30 |
TW202302122A (zh) | 2023-01-16 |
CN117715518A (zh) | 2024-03-15 |
JP2024519222A (ja) | 2024-05-09 |
IL308334A (en) | 2024-01-01 |
CA3217757A1 (en) | 2022-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016122147A1 (ko) | 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도 | |
WO2013094988A1 (en) | Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same | |
WO2016209021A1 (ko) | 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물 | |
WO2018217064A2 (ko) | 형질전환된 t세포를 이용한 자연살해세포의 배양방법 | |
WO2012026712A4 (ko) | Nod2의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물 | |
WO2018097540A9 (ko) | 무혈청면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물 | |
WO2016048107A1 (ko) | 인터페론-감마 또는 인터류킨-1베타를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물 | |
WO2018030806A1 (ko) | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 | |
WO2020101361A1 (ko) | 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법 | |
WO2011142514A1 (ko) | Pias3을 유효성분으로 포함하는 암 또는 면역질환의 예방 또는 치료용 조성물 | |
WO2019117633A1 (ko) | 아토피성 피부염, 탈모, 상처 또는 피부 주름의 개선용 화장료 조성물 및 약학 조성물 | |
WO2021107689A1 (ko) | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 면역관문 억제제를 포함하는 암 치료용 약학 조성물 | |
WO2022240240A1 (ko) | Nk 세포의 동결보존용 조성물 및 이를 포함하는 동결보존 제형 | |
WO2019216623A1 (ko) | 당뇨병 및 비만 치료용 면역관용 세포 백신 및 인슐린 분비 세포의 제조 방법 | |
WO2017146538A1 (ko) | 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2020231058A1 (ko) | 사이토카인 유도 살해세포를 포함하는 활성화 림프구 및 이의 제조 방법 | |
WO2017034244A1 (ko) | 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물 | |
WO2021006670A1 (ko) | 혼합물 4f를 이용한 줄기세포 생물학적 활성 증가용 조성물 | |
WO2021107635A1 (ko) | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 nk 세포를 포함하는 항암 치료용 조성물 | |
WO2013162330A1 (ko) | 키메라 중간엽 줄기세포군, 그의 제조방법 및 편도줄기세포를 이용하여 부갑상선 호르몬을 생산하는 방법 | |
WO2016117960A1 (ko) | 면역질환 치료 효능을 갖는 grim19이 과발현된 중간엽줄기세포 및 이의 용도 | |
WO2022030973A1 (ko) | 종양 침윤성 림프구로부터 역분화된 줄기세포 기억 t세포를 포함하는 세포치료제 조성물 및 그 제조 방법 | |
WO2011115458A2 (ko) | 자가 면역 질환 예방 및 치료용 TNF-α와 IL-21 이중 길항제 | |
WO2019059713A2 (ko) | 자연살해세포의 제조방법 및 그의 용도 | |
WO2021101270A1 (ko) | 자연살해세포 배양용 조성물 및 이를 이용한 자연살해세포 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22807887 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3217757 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 308334 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18559381 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280034209.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/013418 Country of ref document: MX Ref document number: P6002937/2023 Country of ref document: AE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023570249 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023023457 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 806411 Country of ref document: NZ Ref document number: 2022274645 Country of ref document: AU Ref document number: AU2022274645 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022807887 Country of ref document: EP Ref document number: 2023130938 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022807887 Country of ref document: EP Effective date: 20231214 |
|
ENP | Entry into the national phase |
Ref document number: 2022274645 Country of ref document: AU Date of ref document: 20220513 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 523451491 Country of ref document: SA |
|
ENP | Entry into the national phase |
Ref document number: 112023023457 Country of ref document: BR Kind code of ref document: A2 Effective date: 20231109 |